Anxiolytic effects of the melatonin MT2 receptor partial agonist UCM765: Comparison with melatonin and diazepam

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 39, Issue 2, 2012, Pages 318-325

  Ochoa Sanchez, Rafael ^a   Rainer, Quentin ^a   Comai, Stefano ^a   Spadoni, Gilberto ^b   Bedini, Annalida ^b   Rivara, Silvia ^c   Fraschini, Franco ^d   Mor, Marco ^c   Tarzia, Giorgio ^b   Gobbi, Gabriella ^a  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITY OF URBINO   (Italy)

^c UNIVERSITY OF PARMA   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

Author keywords

Anxiety; Elevated plus maze test; Melatonin; Novelty suppressed feeding test; UCM765

Indexed keywords

DIAZEPAM; HORMONE RECEPTOR STIMULATING AGENT; LUZINDOLE; MELATONIN; MELATONIN 2 RECEPTOR; N [2 [(3 METHOXYPHENYL)PHENYLAMINO]ETHYL]ACETAMIDE; UCM 765; UNCLASSIFIED DRUG;

ADULT ANIMAL; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANXIETY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG TARGETING; EXPERIMENTAL TEST; LATENT PERIOD; LOCOMOTION; MALE; MAZE TEST; NONHUMAN; NOVELTY SUPPRESSED FEEDING TEST; OPEN FIELD TEST; RAT; RECEPTOR UPREGULATION; TRANQUILIZING ACTIVITY;

ACETAMIDES; ANILINE COMPOUNDS; ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY; DIAZEPAM; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DRUG PARTIAL AGONISM; FEEDING BEHAVIOR; MALE; MAZE LEARNING; MELATONIN; MOTOR ACTIVITY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, MELATONIN, MT2; TETRAHYDRONAPHTHALENES; TRYPTAMINES;

EID: 84867010418     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2012.07.003     Document Type: Article

References (49)

1. American Psychiatric Association Diagnostic and statistical manual of mental disorders 1994, Author, Washington, D. C. 4th ed.
2. Bambico F.R., Nguyen N.-T., Katz N., Gobbi G. Chronic exposure to cannabinoids during adolescence but not during adulthood impairs emotional behaviour and monoaminergic neurotransmission. Neurobiol Dis 2010, 37:641-655.
3. Bodnoff S., Suranyi-Cadotte B., Aitken D., Quirion R., Meaney M. The effects of chronic antidepressant treatment in an animal model of anxiety. Psychopharmacology (Berl) 1988, 95:298-302.
4. Borsini F., Podhorna J., Marazziti D. Do animal models of anxiety predict anxiolytic-like effects of antidepressants?. Psychopharmacology (Berl) 2002, 163:121-141.
5. Bubenik G.A., Pang S.F. The role of serotonin and melatonin in gastrointestinal physiology: ontogeny, regulation of food intake, and mutual serotonin-melatonin feedback. J Pineal Res 1994, 16:91-99.
6. Caumo W., Levandovski R., Hidalgo M.P.L. Preoperative anxiolytic effect of melatonin and clonidine on postoperative pain and morphine consumption in patients undergoing abdominal hysterectomy: a double-blind, randomized, placebo-controlled study. J Pain 2009, 10:100-108.
7. Crupi R., Mazzon E., Marino A., La Spada G., Bramanti P., Cuzzocrea S., et al. Melatonin treatment mimics the antidepressant action in chronic corticosterone-treated mice. J Pineal Res 2010, 49:123-129.
8. Cruz A.P., Frei F., Graeff F.G. Ethopharmacological analysis of rat behavior on the elevated plus-maze. Pharmacol Biochem Behav 1994, 49:171-176.
9. de Bodinat C., Guardiola-Lemaitre B., Mocaër E., Renard P., Muñoz C., Millan M.J. Agomelatine, the first melatonergic antidepressant: discovery, characterization and development. Nat Rev Drug Discov 2010, 9:628-642.
10. den Boer J., Bosker F., Meesters Y. Clinical efficacy of agomelatine in depression: the evidence. Int Clin Psychopharmacol 2006, 21(Suppl. 1):S21-S24.
11. Domínguez-López S., Mahar I., Bambico F.R., Labonté B., Ochoa-Sánchez R., Leyton M., et al. Short term effects of melatonin and pinealectomy on serotonergic neuronal activity across the light-dark cycle. J Psychopharmacol 2011, 1-15.
12. Dubocovich M., Markowska M. Functional MT1 and MT2 melatonin receptors in mammals. Endocrine 2005, 27:101-110.
13. Eison A.S., Freeman R.P., Guss V.B., Mullins U.L., Wright R.N. Melatonin agonists modulate 5-HT2A receptor-mediated neurotransmission: behavioral and biochemical studies in the rat. J Pharmacol Exp Ther 1995, 273:304-308.
14. Gibbs F.P., Vriend J. The half life-life of melatonin from rat plasma. Endocrinology 1981, 109:1796-1798.
15. Golombek D., Martini M., Cardinali D. Melatonin as an anxiolytic in rats: time dependence and interaction with the central GABAergic system. Eur J Pharmacol 1993, 237:231-236.
16. Golus P., King M.G. The effects of melatonin on open field behavior. Pharmacol Biochem Behav 1981, 15:883-885.
17. Green S. Benzodiazepines, putative anxiolytics and animal models of anxiety. Trends Neurosci 1991, 14:101-104.
18. Gross C., Santarelli L., Brunner D., Zhuang X., Hen R. Altered fear circuits in 5-HT1A receptor KO mice. Biol Psychiatry 2000, 48:1157-1163.
19. Gross P., Nourse R., Wasser T. Ramelteon for insomnia symptoms in a community sample of adults with generalized anxiety disorder: an open label study. J Clin Sleep Med 2009, 5:28-33.
20. Kopp C., Vogel E., Rettori M.-C., Delagrange P., Misslin R. Anxiolytic-like properties of melatonin receptor agonists in mice: involvement of MT1 and/or MT2 receptors in the regulation of emotional responsiveness. Neuropharmacology 2000, 39:1865-1871.
21. Lemoine P., Garfinkel D., Laudon M., Nir T., Zisapel N. Prolonged-release melatonin for insomnia - an open-label long-term study of efficacy, safety, and withdrawal. Ther Clin Risk Manag 2011, 7:301-311.
22. Loiseau F., Le Bihan C., Hamon M., Thiébot M.-H. Effects of melatonin and agomelatine in anxiety-related procedures in rats: interaction with diazepam. Eur Neuropsychopharmacol 2006, 16:417-428.
23. Mantovani M., Pertile R., Calixto J., Santos A., Rodrigues A. Melatonin exerts an antidepressant-like effect in the tail suspension test in mice: evidence for involvement of N-methyl-d-aspartate receptors and the l-arginine-nitric oxide pathway. Neurosci Lett 2003, 343:1-4.
24. Millan M.J. The neurobiology and control of anxious states. Prog Neurobiol 2003, 70:83-244.
25. Millan M.J., Brocco M., Gobert A., Dekeyne A. Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade. Psychopharmacology (Berl) 2005, 177:448-458.
26. Ochoa-Sanchez R., Comai S., Lacoste B., Bambico F.R., Domínguez-Lopez S., Spadoni G., et al. Promotion of non-rapid eye movement sleep and activation of reticular thalamic neurons by a novel MT2 melatonin receptor ligand. J Neurosci 2011, 31:18439-18452.
27. Papp M., Litwa E., Gruca P., Mocaër E. Anxiolytic-like activity of agomelatine and melatonin in three animal models of anxiety. Behav Pharmacol 2006, 17:9-18.
28. Pellow S., Chopin P., File S.E., Briley M. Validation of open: closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Methods 1985, 14:149-167.
29. Prut L., Belzung C. The open field as a paradigm to measure the effects of drugs on anxiety-like behaviors: a review. Eur J Pharmacol 2003, 463:3-33.
30. Raghavendra V., Kaur G., Kulkarni S. Anti-depressant action of melatonin in chronic forced swimming-induced behavioral despair in mice, role of peripheral benzodiazepine receptor modulation. Eur Neuropsychopharmacol 2000, 10:473-481.
31. Rainer Q., Xia L., Guilloux J.P., Gabriel C., Mocaër E., Hen R., et al. Beneficial behavioural and neurogenic effects of agomelatine in a model of depression/anxiety. Int J Neuropsychopharmacol 2011, 1-15.
32. Reiter R. Pineal gland interface between the photoperiodic environment and the endocrine system. Trends Endocrinol Metab 1991, 2:13-19.
33. Reppert S.M. Melatonin receptors: molecular biology of a new family of g protein-coupled receptors. J Biol Rhythms 1997, 12:528-531.
34. Rex A., Stephens D.N., Fink H. Anxiolytic action of diazepam and abecarnil in a modified open field test. Pharmacol Biochem Behav 1996, 53:1005-1011.
35. Rios E.R.V., Venâncio E.T., Rocha N.F.M., Woods D.J., Vasconcelos S., Macedo D., et al. Melatonin: pharmacological aspects and clinical trends. Int J Neurosci 2010, 120:583-590.
36. Rivara S., Lodola A., Mor M., Bedini A., Spadoni G., Lucini V., et al. N-(substituted-anilinoethyl)amides: design, synthesis, and pharmacological characterization of a new class of melatonin receptor ligands. J Med Chem 2007, 50:6618-6626.
37. Rivara S., Vacondio F., Fioni A., Silva C., Carmi C., Mor M., et al. N-(anilinoethyl)amides: design and synthesis of metabolically stable, selective melatonin receptor ligands. ChemMedChem 2009, 4:1746-1755.
38. Rosenstein R.E., Cardinali D.P. Melatonin increases in vivo GABA accumulation in rat hypothalamus, cerebellum, cerebral cortex and pineal gland. Brain Res 1986, 398:403-406.
39. Siemiatkowski M., Sienkiewicz-Jarosz H., CzŁonkowska A.I., Bidziński A., PŁaźnik A. Effects of buspirone, diazepam, and zolpidem on open field behavior, and brain [3H]muscimol binding after buspirone pretreatment. Pharmacol Biochem Behav 2000, 66:645-651.
40. Simonneaux V., Ribelayga C. Generation of the melatonin endocrine message in mammals: a review of the complex regulation of melatonin synthesis by norepinephrine, peptides, and other pineal transmitters. Pharmacol Rev 2003, 55:325-395.
41. Somers J., Goldner E., Waraich P., Hsu L. Prevalence and incidence studies of anxiety disorders: a systematic review of the literature. Can J Psychiatry 2006, 51:100-113.
42. Srinivasan V., Smits M., Spence W., Lowe A.D., Kayumov L., Pandi-Perumal S.R., et al. Melatonin in mood disorders. World J Biol Psychiatry 2006, 7:138-151.
43. Stefański R., Pazxllejko W., Kostowski W., Pałźnik A. The comparison of benzodiazepine derivatives and serotonergic agonists and antagonists in two animal models of anxiety. Neuropharmacology 1992, 31:1251-1258.
44. Stein D., Ahokas A., de Bodinat C. Efficacy of agomelatine in generalized anxiety disorder: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 2008, 28:561-566.
45. Sudhakar P., Gopalakrishna H., Venkatesh V., Amritha R., Sowjanya S., Amrita V., et al. Anxiolytic effect of chronic administration of ursolic acid in rats. J Appl Pharm Sci 2011, 01:68-71.
46. Tian S., Laudon M., Han L., Gao J., Huang F., Yang Y., et al. Antidepressant- and anxiolytic effects of the novel melatonin agonist Neu-P11 in rodent models. Acta Pharmacol Sin 2010, 31:775-783.
47. Weisstaub N.V., Zhou M., Lira A., Lambe E., González-Maeso J., Hornung J.-P., et al. Cortical 5-HT2A receptor signaling modulates anxiety-like behaviors in mice. Science 2006, 313:536-540.
48. Whiting P. GABA-A receptors: a viable target for novel anxiolytics?. Curr Opin Pharmacol 2006, 6:24-29.
49. Witt-Enderby P.A., Bennett J., Jarzynka M.J., Firestine S., Melan M.A. Melatonin receptors and their regulation: biochemical and structural mechanisms. Life Sci 2003, 72:2183-2198.